We are international
Donate
• treatment options TEXT SIZE   
Clinical Trials

NEW TRIALS: HOW TO FIND THEM

Clinical trials offer patients access to promising new treatments which have not yet been approved. They offer an opportunity to help make new treatments available to all patients by helping to advance science. Patients in clinical trials receive high-quality care and are carefully followed.

HOW TO FIND INFORMATION ON THE LATEST TRIALS

The IMF’s Myeloma Matrix is a great website resource that lists myeloma drugs currently under development and tracks them from discovery to approval. The Myeloma Matrix is continuously updated by the InfoLine Team so visitors to the page get up-to-the-minute status information about myeloma drugs in all stages of development—from Pre-Clinical to FDA Approved.

REFERENCES

The IMF is pleased to offer a number of ways to help you locate a clinical trial which may be appropriate.

DRUGS & PROCEDURES IN CLINICAL TRIALS
CLINICAL TRIAL FACILITIES AND COOPERATIVE GROUPS
SEARCH TOOLS
CLINICAL TRIALS INFORMATION
Before new drugs or procedures can be approved for use in treating myeloma, they must go through clinical trials to prove that they are safe and more effective than currently-available treatments
MYELOMA MATRIX
Drugs In Development or Recently Approved
The Myeloma Matrix lists drugs currently under development and tracks them from discovery to approval.

Elotuzumab (HuLuc63)
Elotuzumab (formerly known as HuLuc63) is a monoclonal antibody that targets SLAMF7, a cell surface glycoprotein highly expressed on myeloma cells and hematopoietic cells but not expressed on nonhematopoietic cells . Elotuzumab is currently in clinical trials for newly diagnosed, previously untreated and relapsed or refractory myeloma.

Denosumab
Denosumab is a fully human monoclonal antibody against RANK ligand, a protein critical for osteoclast formation, maturation, and function. It is approved for the prevention of skeletal related events in patients with bone metastases from solid tumors, but its effects in patients with multiple myeloma need to be further studied. Currently, a clinical trial of denosumab to help determine if it can prevent skeletal related events in multiple myeloma is under way.

Ixazomib
Ixazomib (MLN9708) is an investigational oral proteasome inhibitor, which is being studied in multiple myeloma (MM), systemic light-chain (AL) amyloidosis and other malignancies.

Selinexor
Selinexor is a novel, first-in-class, orally administered “Selective Inhibitor of Nuclear Export” (SINE™). Selinexor blocks the ability of cancer cells to pump out, or export, tumor suppressor proteins from their cell nuclei. Tumor suppressor proteins detect cancerous DNA changes and induce cancer cell death. Selinexor also reduces levels of key cancer-causing proteins, thus reducing the growth of cancer.

ExAblate (MRI-guided Focused Ultrasound Surgery)
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone and Multiple Myeloma Tumors for the Palliation of Pain in Patients Who Are Not Candidates for Radiation